Currently submitted to: JMIR Research Protocols
Date Submitted: Dec 16, 2019
Open Peer Review Period: Dec 16, 2019 - Feb 10, 2020
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note “no longer under consideration” will appear above).
Peer-review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a “Peer-Review Me” button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed “version of record” (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Influence of PARAmedical Interventions on Patient ACTivation in the Cancer Care Pathway : Protocol for implementation of the PAM 13 (PARACT multicentric study)
The increase in the number of cancers and the chronicization of care for some of them is a major problem for the French care system. Thus, patient empowerment is a goal sought in chronic pathologies for several years. The Patient Activation Measure (PAM) has been developed to objectify the evolution of patients in this activation process. Indeed, patients with a high level of activation have less inappropriate use of care and better treatment adherence. Therefore, the implementation of an activation measure via the PAM 13 could highlight the patient’s needs and adapt the care to their needs.
The main objectif of this study is to implement the PAM 13 as a tool for measuring the patients activation in care settings for cancer patients.
This is a quasi-interventional, multicentric study open to implementation. The patient will be followed for 12 months. During this follow-up, the different patient contacts with the nurses and other health caregiver will be collected, as well as nursing strategies. The completion of the PAM 13, EQ-5D, HAD scale, and REALM R questionnaires will be done at baseline, at 6 months, and at 12 months. The completion will be carried out by a nurse.
Data collection for this study is ongoing. To date, 170 patients have participated in 3 of the 5 establishments of treatment of cancer.
This pioneering implementation study in French cancer centers, would improve the implement targeted nursing interventions, in order to offer the patient a personalized care pathway. On the other hand, the measurement of the level of activation and the implementation of measures intended to increase it, would be a major advantage in reducing social health inequalities. Clinical Trial: ClinicalTrials.gov Identifier: NCT03240341 ANSM : 2017-A00235-48 IDRCB: 2017-A00235-48
Request queued. Please wait while the file is being generated. It may take some time.
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.